


PHARMACEUTICAL 2017



CYTOKINETICS INC Rank 29 of 313





PHARMACEUTICAL 2017



CYTOKINETICS INC Rank 29 of 313



The relative strengths and weaknesses of CYTOKINETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CYTOKINETICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 412% points. The greatest weakness of CYTOKINETICS INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 555% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	158,633
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	33,258
Liabilities, Non-Current	27,381
Other Assets	7,872
Other Compr. Net Income	-12
Other Expenses	2,698
Other Liabilities	15,142
Other Net Income	464
Property and Equipment	3,637
Research and Development	59,897
Revenues	106,407
Selling, General and Administrative Expense	27,823

Output Variable	Value in 1000 USD
Assets	170,142
Liabilities	75,781
Expenses	90,418
Stockholders Equity	94,361
Net Income	16,453
Comprehensive Net Income	16,447
Economic Capital Ratio	139%